Nicox to Acquire Aciex Therapeutics, Inc.
Nicox S.A. today announced it has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. The completion of the acquisition remains subject to the approval of Nicox's shareholders and other customary conditions.
WilmerHale is representing Aciex Therapeutics in this deal, with a team being led by Partner Josh Fox that includes Partners A. William Caporizzo, Jeff Hermanson and Belinda Juran, a well as Senior Associates Livingston Miller and Meghan Walsh, and Associate Colin Beavais.
The formal press release with full details of the transaction can be found on Nicox's site.